Mirikizumab - IV

DRUG3 trials

Sponsors

Eli Lilly and Company, Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives

Conditions

Crohn Disease (CD)Healthy

Phase 1

A Study of Mirikizumab (LY3074828) in Healthy Participants

CompletedNCT02568423

Eli Lilly and CompanyHealthy

Start: 2015-12-02End: 2018-10-24Updated: 2024-02-08

A Study of Mirikizumab in Healthy Chinese Participants

CompletedNCT04137380

Eli Lilly and CompanyHealthy

Start: 2019-12-04End: 2020-12-11Updated: 2024-01-26

Phase 4

Efficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's Disease

RecruitingNCT07292012

Groupe d'Etude Therapeutique des Affections Inflammatoires DigestivesCrohn Disease (CD)

Start: 2026-05-11End: 2028-11-01Target: 75Updated: 2026-05-26

Related Papers

S1108 Safety, Tolerability, and Pharmacokinetics of Mirikizumab in Chinese Healthy Subjects: Results From a Phase 1 Study

The American Journal of Gastroenterology2023-10-01

Mirikizumab Pharmacokinetics in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase III LUCENT Studies.

2023-08-2317 citations